The Company’s WT1 cancer vaccine has shown increased survival compared to historical controls in patients with acute myeloid leukemia ; and has also shown encouraging early data in mesothelioma. SELLAS will initiate further studies across at least two more cancer indications by Q4 2015 and Q1 2016, and plans to start a Phase 3 clinical study in early 2016.
